Literature DB >> 1506859

Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination.

C Theda1, A B Moser, J M Powers, H W Moser.   

Abstract

Changes in fatty acid composition of complex lipids were analyzed in postmortem white matter from a patient with late onset adrenoleukodystrophy (ALD). The specimen showed three regions with progressive myelin breakdown: morphologically normal white matter; areas with active demyelination and perivascular lymphocyte and macrophage infiltration; and areas with marked gliosis. In the morphologically intact region, cholesterol esters were similar in amount and fatty acid composition to those in control tissue, although marked changes were observed in the actively demyelinating area. Galactolipids in these areas were also similar to those in controls. In contrast, glycerophospholipids were increased in amount and in very long chain fatty acids (VLCFA), which are the hallmark of ALD, at the active edge of the demyelinative lesion and even in the apparently intact sample. Further fractionation of the glycerophospholipids by high performance liquid chromatography showed a significant (up to 39-fold) accumulation of hexacosanoic acid (C26:0) in phosphatidylcholine, but not in other phosphatidyl derivatives. The consistent increases in phosphatidylcholine VLCFA in all samples from the ALD brain, which are postulated to represent progressive stages in the development of the disorder, suggest that phosphatidylcholine may be involved in antigen formation and may underlie an immunological basis for the pathogenesis of ALD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506859     DOI: 10.1016/0022-510x(92)90028-j

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  31 in total

1.  Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy.

Authors:  Mushfiquddin Khan; Jaspreet Singh; Anne G Gilg; Takuhiro Uto; Inderjit Singh
Journal:  J Lipid Res       Date:  2010-02-20       Impact factor: 5.922

2.  Glycerol trioleate/glycerol trierucate therapy in X-linked adrenoleukodystrophy: saturated and unsaturated fatty acids in blood cells. Implications for the follow-up.

Authors:  M Ruiz; T Pampols; M Girós
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

3.  Effects of exogenous hexacosanoic acid on biochemical myelin composition in weaning and post-weaning rats.

Authors:  A Di Biase; C Avellino; F Pieroni; T Quaresima; A Grisolia; M Cappa; S Salvati
Journal:  Neurochem Res       Date:  1997-03       Impact factor: 3.996

Review 4.  Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.

Authors:  Inderjit Singh; Aurora Pujol
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

5.  The Pex1-G844D mouse: a model for mild human Zellweger spectrum disorder.

Authors:  Shandi Hiebler; Tomohiro Masuda; Joseph G Hacia; Ann B Moser; Phyllis L Faust; Anita Liu; Nivedita Chowdhury; Ning Huang; Amanda Lauer; Jean Bennett; Paul A Watkins; Donald J Zack; Nancy E Braverman; Gerald V Raymond; Steven J Steinberg
Journal:  Mol Genet Metab       Date:  2014-01-23       Impact factor: 4.797

6.  Brain endothelial dysfunction in cerebral adrenoleukodystrophy.

Authors:  Patricia L Musolino; Yi Gong; Juliet M T Snyder; Sandra Jimenez; Josephine Lok; Eng H Lo; Ann B Moser; Eric F Grabowski; Matthew P Frosch; Florian S Eichler
Journal:  Brain       Date:  2015-09-15       Impact factor: 13.501

7.  Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy.

Authors:  Quentin Raas; Malu-Clair van de Beek; Sonja Forss-Petter; Inge Me Dijkstra; Abigail Deschiffart; Briana C Freshner; Tamara J Stevenson; Yorrick Rj Jaspers; Liselotte Nagtzaam; Ronald Ja Wanders; Michel van Weeghel; Joo-Yeon Engelen-Lee; Marc Engelen; Florian Eichler; Johannes Berger; Joshua L Bonkowsky; Stephan Kemp
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

8.  Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil).

Authors:  M Rasmussen; A B Moser; J Borel; S Khangoora; H W Moser
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

9.  Thrombocytopenia induced by erucic acid therapy in patients with X-linked adrenoleukodystrophy.

Authors:  S Zierz; R Schröder; C J Unkrig
Journal:  Clin Investig       Date:  1993-10

10.  Erucic acid is differentially taken up and metabolized in rat liver and heart.

Authors:  Cameron C Murphy; Eric J Murphy; Mikhail Y Golovko
Journal:  Lipids       Date:  2008-03-19       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.